Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world experience with front-line metronomic low-dose weekly decitabine and venetoclax in elderly and/or frail patients with MDS or AML

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAdit SinghalDMDavid Mueller

Discussion

Loading...

Member takes

Overview

Retrospective review shows low-dose decitabine and venetoclax improves overall survival in elderly patients with MDS or AML, suggesting effective treatment alternatives.

Key Points

  • Assess real-world outcomes of low-dose weekly decitabine and venetoclax in elderly and frail patients with MDS or AML.
  • Retrospective review of patients with newly diagnosed MDS or AML
  • Patients received low-dose decitabine and venetoclax as front-line therapy
  • Key outcomes included overall response rate and complete response rates
  • Overall response rate (ORR) was 28% and complete response rate was 21%
  • Median overall survival (OS) for particular genetic subgroups was between 3.7 and 8.1 months
  • 47% of patients completed three cycles without interruptions, reflecting improved quality of life

Cite This Study

Singhal et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da09https://doi.org/10.1182/blood-2025-5186
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations
  2. 2Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  3. 3A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).2024 · 2 citations
  4. 4Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial2025 · 1 citations
  5. 5Low dose weekly HMA-venetoclax dosing is associated with greater cost-effective efficacy than standard dosing in AML/MDS: Real-world evidence2025